BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q2 EPS by 6c; Guides FY11
Tweet Send to a FriendGet Alerts BMRN Hot Sheet
Price: $64.41 +0.62%
Revenue Growth %: -100.0%
Financial Fact:
Total revenues: 127.93M
Today's EPS Names:
RAVN, CAMT, HAST, More
Revenue Growth %: -100.0%
Financial Fact:
Total revenues: 127.93M
Today's EPS Names:
RAVN, CAMT, HAST, More
Trade BMRN Now!
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q2 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $110.63 million versus the consensus estimate of $105.9 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Alvarion Ltd (ALVR) Narrows Q1 Loss
- ReneSola Ltd. (SOL) Posts Q1 Loss of 45c/ADS; Guides Q2, FY13 Shipments
Create E-mail Alert Related Categories
Earnings, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
